Bioavailability Enhancement: Integrated Solutions from Early Development to GMP Manufacture
When poor solubility threatens the therapeutic performance of your drug, we bridge the gap between drug substance and drug product.
In this expert-led workshop, join industry specialists Jonathan Loughrey and Dr. Terry Ernest as they explore practical, science driven strategies to overcome bioavailability challenges and accelerate robust, manufacturable formulations.
Secure your spot today and unlock the full potential of your drug development programme.
Join us in-person
Date: Tuesday 12th May 2026
Location: Tivoli Hotel, Copenhagen, Denmark
Time: 9:30am – 4:30pm (CET)
Spaces are limited
To secure your place, please confirm your attendance as soon as possible by completing the registration form.
Agenda
| Topic | Speaker | Duration | Time |
|---|---|---|---|
Arrival & breakfast (networking) |
30 mins |
09:30 – 10:00 |
|
Welcome & intros |
Brian Eastwood |
10 mins |
10:00 – 10:10 |
|
Drug Substance Characterisation Baseline physicochemical properties Key solubility indicators In silico tools CS classifications Case studies and key examples of small molecules, PROTACs / TPDs, peptides and complex molecules Q&A |
Dr. Jonathan Loughrey |
30 mins
10 mins |
10:10 – 10:50 |
|
QbD Aligned Approach to Platform Feasibility – Considerations for platform development based on molecule properties and QTPP Case study examples Q&A |
Dr. Terry Ernest |
30 mins
10 mins |
10:50 – 11:30 |
Break |
10 mins |
11:30 – 11:40 |
|
|
Nominating early formulations for bioavailability enhancement Identifying target formulations Paediatric formulations Case studies and key examples Q&A |
Dr. Jonathan Loughrey |
30 mins
10 mins |
11:40 – 12:20 |
|
Dosage Form Design and Process Development – Scale up strategies including modelling and risk assessment principles Demonstrating process and formulation robustness and predicting PK performance Case study examples Q&A |
Dr. Terry Ernest |
30 mins
10 mins |
12:20 – 13:00 |
Lunch |
45 mins |
13:00 – 13:45 |
|
|
Research Advancements in Amorphous Drug Delivery Systems Q&A |
Ines C B Martins, UCPH |
30 mins 10 mins |
13:45 – 14:25 |
|
Advanced and Emerging Technologies The role of AI in refining formulations Case studies and key examples Q&A |
Dr. Jonathan Loughrey |
30 mins
10 mins |
14:25 – 15:05 |
|
Patient Centric Principles – Patient focused approaches and considerations associated with dosage form design Case study examples Q&A |
Dr. Terry Ernest |
30 mins
10 mins |
15:05 – 15:45 |
Raffle & networking |
All |
45 mins |
15:45 – 16:30 |
Your industry experts will be:
Dr. Terry Ernest
Director of Manufacturing Science & Technology,
Almac Pharma Services
Connect on LinkedIn
Dr. Jonathan Loughrey
Director of Chemical Development,
Almac Sciences
Connect on LinkedIn
Sander van den Ban
Director of Operations – Manufacturing,
Almac Pharma Services
Connect on LinkedIn
Brian Eastwood
Head of Business Development and Strategic Relationships,
Almac Pharma Services
Connect on LinkedIn
Peder Fode
Senior Business Development Manager,
Almac Pharma Services
Connect on LinkedIn
Aideen Fox
Business Development Manager,
Almac Sciences
Connect on LinkedIn
